Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Intratumoral Ipilimumab · 1 trial · 1 indication
The percentage of patients with surgery delayed possibly related to the study drug.
| Arm | Type | Description |
|---|---|---|
| Intratumoral Ipilimumab | EXPERIMENTAL | Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure. |
| Name | Type | Description |
|---|---|---|
| Intratumoral Ipilimumab | DRUG | Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor. |
Inclusion Criteria: * Patients with SCCHN who are planned for surgical resection and in the opinion of the surgeon are able to safely undergo tissue biopsy plus intratumoral (IT) injection in advance, with special consideration given to risk of occlusion or compression of airway or major vessels in...
Intratumoral Ipilimumab is an investigational small molecule being studied for the treatment of squamous cell carcinoma of the head and neck. It is administered directly into the tumor and is currently in Phase 1 clinical development for this indication.
Intratumoral Ipilimumab is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with squamous cell carcinoma of the head and neck.
Intratumoral Ipilimumab is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is active but not recruiting participants, with a planned enrollment of 18 patients.
Intratumoral Ipilimumab is being studied in a single Phase 1 clinical trial with the identifier NCT02812524, titled "Ipilimumab for Head and Neck Cancer Patients." The trial is active but not recruiting, enrolling 18 patients with squamous cell carcinoma of the head and neck in the United States.
Intratumoral Ipilimumab is a formulation of ipilimumab that is administered directly into the tumor, rather than systemically. The clinical trial NCT02812524 evaluates this intratumoral route of administration in patients with squamous cell carcinoma of the head and neck.